The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Titova N.V.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Katunina E.A.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Tairova R.T.

Federal Center of Brain Research and Neurotechnologies

Senko I.V.

Sklifosovsky Research Institute for Emergency Care;
Federal Center for Brain and Neurotechnologies

Dzhafarov V.M.

Federal Neurosurgery Center

Malykhina E.A.

Pirogov Russian National Research Medical University;
Federal Center for Brain and Neurotechnologies

The problem of pharmacoresistant tremor in Parkinson’s disease and essential tremor

Authors:

Titova N.V., Katunina E.A., Tairova R.T., Senko I.V., Dzhafarov V.M., Malykhina E.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(10): 24‑30

DOI: 10.17116/jnevro202212210124

Views: 4036

Downloaded: 174

Download PDF (RU)
Contact the author
Table of contents

THE PROBLEM OF PHARMACORESISTANT TREMOR IN PARKINSON’S DISEASE AND ESSENTIAL TREMOR
THE PROBLEM OF PHARMACORESISTANT TREMOR IN PARKINSON’S DISEASE AND ESSENTIAL TREMOR

To cite this article:

Titova NV, Katunina EA, Tairova RT, Senko IV, Dzhafarov VM, Malykhina EA. The problem of pharmacoresistant tremor in Parkinson’s disease and essential tremor. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(10):24‑30. (In Russ.)
https://doi.org/10.17116/jnevro202212210124

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
The asso­ciation of single-nucleotide poly­morphism rs6265 of the brain-derived neurotrophic factor gene with clinical features in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):82-88
Sarcopenia as a non-motor symptom of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):15-22
Asso­ciation of inflammation and chro­nic fati­gue syndrome in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):79-87
Electric acti­vity of the brain at early and late clinical stages of expe­rimental mode­ling of Parkinson’s disease, an impact of hema­ntane. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):129-134
Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34
Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72
Clinical presentation and diagnosis of Parkinson’s disease in patients with schi­zophrenia spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):73-80
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99
Problems in orga­nizing neurosurgical care for patients with Parkinson’s disease in the Russian Fede­ration. Burdenko's Journal of Neurosurgery. 2024;(3):5-13

MR-guided focused ultrasound (MRg-FUS) is a new noninvasive method for the treatment of contralateral disabling and pharmacoresistant tremor. Clinical studies have confirmed the high efficacy and safety of using MRg-FUS in patients with essential tremor and Parkinson’s disease, in short and long-term studies. Advantages of this method in comparison with currently used invasive and noninvasive technics, potential brain target areas, the possibility of bilateral intervention, indications and contraindications are discussed.

Keywords:

tremor
pharmacoresistant
thalamotomy
focused ultrasound
MR-guided focused ultrasound
essential tremor
Parkinson’s disease

Authors:

Titova N.V.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Katunina E.A.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Tairova R.T.

Federal Center of Brain Research and Neurotechnologies

Senko I.V.

Sklifosovsky Research Institute for Emergency Care;
Federal Center for Brain and Neurotechnologies

Dzhafarov V.M.

Federal Neurosurgery Center

Malykhina E.A.

Pirogov Russian National Research Medical University;
Federal Center for Brain and Neurotechnologies

Received:

07.03.2022

Accepted:

23.06.2022

List of references:

  1. Louis ED, Barnes L, Albert SM, et al. Correlates of functional disability in essential tremor. Mov Disord. 2001;16(5):914-920.  https://doi.org/10.1002/mds.1184
  2. Huang H, Yang X, Zhao Q, et al. Prevalence and Risk Factors of Depression and Anxiety in Essential Tremor Patients: A Cross-Sectional Study in Southwest China. Front Neurol. 2019;10:1194. https://doi.org/10.3389/fneur.2019.01194
  3. Hopfner F, Deuschl G. Managing Essential Tremor. Neurotherapeutics. 2020;17(4):1603-1621. Erratum in: Neurotherapeutics. 2021 Jul;18(3):2132. https://doi.org/10.1007/s13311-020-00899-2
  4. Kamble N, Pal PK. Tremor syndromes: A review. Neurol India. 2018;66(Supplement):S36-S47.  https://doi.org/10.4103/0028-3886.226440
  5. Louis ED, Marder K, Cote L, et al. Differences in the prevalence of essential tremor among elderly African Americans, whites, and Hispanics in northern Manhattan, NY. Arch Neurol. 1995;52(12):1201-1205. https://doi.org/10.1001/archneur.1995.00540360079019
  6. Louis ED. The Roles of Age and Aging in Essential Tremor: An Epidemiological Perspective. Neuroepidemiology. 2019;52(1-2):111-118.  https://doi.org/10.1159/000492831
  7. Louis ED, Broussolle E, Goetz CG, Krack P, Kaufmann P, Mazzoni P. Historical underpinnings of the term essential tremor in the late 19th century. Neurology. 2008;71(11):856-859.  https://doi.org/10.1212/01.wnl.0000325564.38165.d1
  8. Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord. 2010;25(5):534-541.  https://doi.org/10.1002/mds.22838
  9. Hopfner F, Ahlf A, Lorenz D, et al. Early- and late-onset essential tremor patients represent clinically distinct subgroups. Mov Disord. 2016;31(10):1560-1566. https://doi.org/10.1002/mds.26708
  10. Thanvi B, Lo N, Robinson T. Essential tremor-the most common movement disorder in older people. Age Ageing. 2006;35(4):344-349.  https://doi.org/10.1093/ageing/afj072
  11. Koller WC, Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology. 1989;39(12):1587-1588. https://doi.org/10.1212/wnl.39.12.1587
  12. Louis ED, Rios E, Henchcliffe C. How are we doing with the treatment of essential tremor (ET)?: Persistence of patients with ET on medication: data from 528 patients in three settings. Eur J Neurol. 2010;17(6):882-884.  https://doi.org/10.1111/j.1468-1331.2009.02926.x
  13. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939-953.  https://doi.org/10.1016/S1474-4422(18)30295-3
  14. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525-535.  https://doi.org/10.1016/S1474-4422(06)70471-9
  15. Lee A, Gilbert RM. Epidemiology of Parkinson Disease. Neurol Clin. 2016;34(4):955-965.  https://doi.org/10.1016/j.ncl.2016.06.012
  16. Alves G, Larsen JP, Emre M, et al. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord. 2006;21(8):1123-1130. https://doi.org/10.1002/mds.20897
  17. Eisinger RS, Martinez-Ramirez D, Ramirez-Zamora A, et al. Parkinson’s disease motor subtype changes during 20 years of follow-up. Parkinsonism Relat Disord. 2020;76:104-107.  https://doi.org/10.1016/j.parkreldis.2019.05.024
  18. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990;40(10):1529-1534. https://doi.org/10.1212/wnl.40.10.1529
  19. Zach H, Dirkx MF, Roth D, et al. Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease. Neurology. 2020;95(11):e1461-e1470. https://doi.org/10.1212/WNL.0000000000010316
  20. Lundervold DA, Pahwa R, Ament PA, Corbin DE. Validity of clinical and patient ratings of tremor disability among older adults. Parkinsonism Relat Disord. 2003;10(1):15-18.  https://doi.org/10.1016/s1353-8020(03)00061-0
  21. Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology. 2011;77(19):1752-1755. https://doi.org/10.1212/WNL.0b013e318236f0fd
  22. Tasker RR. Deep brain stimulation is preferable to thalamotomy for tremor suppression. Surg Neurol. 1998;49(2):145-154.  https://doi.org/10.1016/s0090-3019(97)00459-x
  23. Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol. 1997;42(3):292-299.  https://doi.org/10.1002/ana.410420304
  24. Negida A, Elminawy M, El Ashal G, et al. Subthalamic and Pallidal Deep Brain Stimulation for Parkinson’s Disease. Cureus. 2018;10(2):e2232. https://doi.org/10.7759/cureus.2232
  25. Gusev EI, Katunina EA, Titova NV. Deep brain stimulation for the treatment of Parkinson’s disease. Vestnik Roszdravnadzora. 2016;6:54-60. (In Russ.).
  26. Alterman RL. One step backward: Magnetic resonance guided focused ultrasound thalamotomy for the treatment of medically refractory tremor. Ann Neurol. 2017;81(3):348-350.  https://doi.org/10.1002/ana.24893
  27. Louis ED, Patel A, Gerrard JL. What is the pathway forward for the surgical management of essential tremor? Ann Neurol. 2017;81(3):351-353.  https://doi.org/10.1002/ana.24892
  28. Galkin MV. The use of transcranial focused ultrasound in CNS diseases. Zhurnal Voprosy Neirokhirurgii Imeni N.N. Burdenko. 2016;80(2):108-118. (In Russ., In Engl.). https://doi.org/10.17116/neiro2016802108-118
  29. D’Souza M, Chen KS, Rosenberg J, et al. Impact of skull density ratio on efficacy and safety of magnetic resonance-guided focused ultrasound treatment of essential tremor. J Neurosurg. 2019;132(5):1392-1397. https://doi.org/10.3171/2019.2.JNS183517
  30. Meng Y, Solomon B, Boutet A, et al. Magnetic resonance-guided focused ultrasound thalamotomy for treatment of essential tremor: A 2-year outcome study. Mov Disord. 2018;33(10):1647-1650. https://doi.org/10.1002/mds.99
  31. Elias WJ, Lipsman N, Ondo WG, et al. A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor. N Engl J Med. 2016;375(8):730-739.  https://doi.org/10.1056/NEJMoa1600159
  32. Halpern CH, Santini V, Lipsman N, et al. Three-year follow-up of prospective trial of focused ultrasound thalamotomy for essential tremor. Neurology. 2019;93(24):e2284-e2293. https://doi.org/10.1212/WNL.0000000000008561
  33. Park YS, Jung NY, Na YC, Chang JW. Four-year follow-up results of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. Mov Disord. 2019;34(5):727-734.  https://doi.org/10.1002/mds.27637
  34. Sinai A, Nassar M, Eran A, et al. Magnetic resonance-guided focused ultrasound thalamotomy for essential tremor: a 5-year single-center experience. J Neurosurg. 2019;34(8):1-8.  https://doi.org/10.3171/2019.3.JNS19466
  35. Schreglmann SR, Bauer R, Hägele-Link S, et al. Unilateral cerebellothalamic tract ablation in essential tremor by MRI-guided focused ultrasound. Neurology. 2017;88(14):1329-1333. https://doi.org/10.1212/WNL.0000000000003795
  36. Gallay MN, Moser D, Jeanmonod D. MR-guided focused ultrasound cerebellothalamic tractotomy for chronic therapy-resistant essential tremor: anatomical target reappraisal and clinical results. J Neurosurg. 2020;34(5):1-10. Epub ahead of print. https://doi.org/10.3171/2019.12.JNS192219
  37. Paff M, Boutet A, Neudorfer C, et al. Magnetic Resonance-Guided Focused Ultrasound Thalamotomy to Treat Essential Tremor in Nonagenarians. Stereotact Funct Neurosurg. 2020;98(3):182-186.  https://doi.org/10.1159/000506817
  38. Mohammed N, Patra D, Nanda A. A meta-analysis of outcomes and complications of magnetic resonance-guided focused ultrasound in the treatment of essential tremor. Neurosurg Focus. 2018;44(2):E4. Erratum in: Neurosurg Focus. 2018;45(1):E16.  https://doi.org/10.3171/2017.11.FOCUS17628
  39. Jung NY, Park CK, Chang WS, et al. Effects on cognition and quality of life with unilateral magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. Neurosurg Focus. 2018;44(2):E8.  https://doi.org/10.3171/2017.11.FOCUS17625
  40. Gasca-Salas C, Guida P, Piredda R, et al. Cognitive safety after unilateral magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. J Neurol Neurosurg Psychiatry. 2019;90(7):830-831.  https://doi.org/10.1136/jnnp-2018-320129
  41. Ferreira JJ, Mestre TA, Lyons KE, et al; MDS Task Force on Tremor and the MDS Evidence Based Medicine Committee. MDS evidence-based review of treatments for essential tremor. Mov Disord. 2019;34(7):950-958.  https://doi.org/10.1002/mds.27700
  42. Alshaikh J, Fishman PS. Revisiting bilateral thalamotomy for tremor. Clin Neurol Neurosurg. 2017;158:103-107.  https://doi.org/10.1016/j.clineuro.2017.04.025
  43. Iorio-Morin C, Yamamoto K, Sarica C, et al. Bilateral Focused Ultrasound Thalamotomy for Essential Tremor (BEST-FUS Phase 2 Trial). Mov Disord. 2021;36(11):2653-2662. https://doi.org/10.1002/mds.28716
  44. Weidman EK, Kaplitt MG, Strybing K, Chazen JL. Repeat magnetic resonance imaging-guided focused ultrasound thalamotomy for recurrent essential tremor: case report and review of MRI findings. J Neurosurg. 2019;67(7):1-6.  https://doi.org/10.3171/2018.10.JNS181721
  45. Harary M, Segar DJ, Hayes MT, Cosgrove GR. Unilateral Thalamic Deep Brain Stimulation Versus Focused Ultrasound Thalamotomy for Essential Tremor. World Neurosurg. 2019;126:e144-e152. https://doi.org/10.1016/j.wneu.2019.01.281
  46. Ravikumar VK, Parker JJ, Hornbeck TS, et al. Cost-effectiveness of focused ultrasound, radiosurgery, and DBS for essential tremor. Mov Disord. 2017;32(8):1165-1173. https://doi.org/10.1002/mds.26997
  47. Li C, Gajic-Veljanoski O, Schaink AK, et al. Cost-Effectiveness of Magnetic Resonance-Guided Focused Ultrasound for Essential Tremor. Mov Disord. 2019;34(5):735-743.  https://doi.org/10.1002/mds.27587
  48. Magara A, Bühler R, Moser D, et ala. First experience with MR-guided focused ultrasound in the treatment of Parkinson’s disease. J Ther Ultrasound. 2014;2:11.  https://doi.org/10.1186/2050-5736-2-11
  49. Schlesinger I, Eran A, Sinai A, et al. MRI Guided Focused Ultrasound Thalamotomy for Moderate-to-Severe Tremor in Parkinson’s Disease. Parkinsons Dis. 2015;2015:219149. https://doi.org/10.1155/2015/219149
  50. Zaaroor M, Sinai A, Goldsher D, et al. Magnetic resonance-guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson’s disease and essential tremor cases. J Neurosurg. 2018;128(1):202-210.  https://doi.org/10.3171/2016.10.JNS16758
  51. Fasano A, Llinas M, Munhoz RP, et al. MRI-guided focused ultrasound thalamotomy in non-ET tremor syndromes. Neurology. 2017;89(8):771-775.  https://doi.org/10.1212/WNL.0000000000004268
  52. Fasano A, De Vloo P, Llinas M, et al. Magnetic Resonance Imaging-Guided Focused Ultrasound Thalamotomy in Parkinson Tremor: Reoperation After Benefit Decay. Mov Disord. 2018;33(5):848-849.  https://doi.org/10.1002/mds.27348
  53. Bond AE, Shah BB, Huss DS, et al. Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2017;74(12):1412-1418. https://doi.org/10.1001/jamaneurol.2017.3098
  54. Sperling SA, Shah BB, Barrett MJ, et al. Focused ultrasound thalamotomy in Parkinson disease: Nonmotor outcomes and quality of life. Neurology. 2018;91(14):e1275-e1284. https://doi.org/10.1212/WNL.0000000000006279
  55. Ito H, Fukutake S, Yamamoto K, et al. Magnetic Resonance Imaging-guided Focused Ultrasound Thalamotomy for Parkinson’s Disease. Intern Med. 2018;57(7):1027-1031. https://doi.org/10.2169/internalmedicine.9586-17
  56. Yamamoto K, Ito H, Fukutake S, et al. Ventralis intermedius thalamotomy with focused ultrasound for patients with low skull density ratio. Mov Disord. 2019;34(8):1239-1240. https://doi.org/10.1002/mds.27726
  57. Moosa S, Martínez-Fernández R, Elias WJ, et al. The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson’s disease. Mov Disord. 2019;34(9):1243-1251. https://doi.org/10.1002/mds.27779
  58. Sinai A, Nassar M, Sprecher E, et al. Focused Ultrasound Thalamotomy in Tremor Dominant Parkinson’s Disease: Long-Term Results. J Parkinsons Dis. 2022;12(1):199-206.  https://doi.org/10.3233/JPD-212810
  59. Martínez-Fernández R, Rodríguez-Rojas R, Del Álamo M, et al. Focused ultrasound subthalamotomy in patients with asymmetric Parkinson’s disease: a pilot study. Lancet Neurol. 2018;17(1):54-63.  https://doi.org/10.1016/S1474-4422(17)30403-9
  60. Jung NY, Park CK, Kim M, et al. The efficacy and limits of magnetic resonance-guided focused ultrasound pallidotomy for Parkinson’s disease: a Phase I clinical trial. J Neurosurg. 2018;23(7):1-9.  https://doi.org/10.3171/2018.2.JNS172514
  61. A Study to Evaluate the Safety and Efficacy of ExAblate Subthalomotomy for the Treatment of Parkinson’s Disease Motor Features. ClinicalTrials.gov Identifier: NCT03454425. https://clinicaltrials.gov/ct2/show/NCT03454425
  62. Martínez-Fernández R, Máñez-Miró JU, Rodríguez-Rojas R, et al. Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease. N Engl J Med. 2020;383(26):2501-2513. https://doi.org/10.1056/NEJMoa2016311
  63. ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson’s Disease. ClinicalTrials.gov Identifier: NCT03319485. https://clinicaltrials.gov/ct2/show/results/NCT03319485
  64. Gallay MN, Moser D, Rossi F, et al. MRgFUS Pallidothalamic Tractotomy for Chronic Therapy-Resistant Parkinson’s Disease in 51 Consecutive Patients: Single Center Experience. Front Surg. 2020;6:76.  https://doi.org/10.3389/fsurg.2019.00076
  65. A Feasibility Study on the Safety and Preliminary Efficacy of Bilateral Subthalamotomy Using MRgFUS for Treatment of PD. ClinicalTrials.gov Identifier: NCT03964272. https://clinicaltrials.gov/ct2/show/NCT03964272
  66. Meng Y, Pople CB, Kalia SK, et al. Cost-effectiveness analysis of MR-guided focused ultrasound thalamotomy for tremor-dominant Parkinson’s disease. J Neurosurg. 2020;23(8):1-6.  https://doi.org/10.3171/2020.5.JNS20692
  67. Elias WJ, Huss D, Voss T, et al. A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2013;369(7):640-648.  https://doi.org/10.1056/NEJMoa1300962
  68. Chang JW, Park CK, Lipsman N, et al. A prospective trial of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor: Results at the 2-year follow-up. Ann Neurol. 2018;83(1):107-114.  https://doi.org/10.1002/ana.25126
  69. Yamamoto K, Ito H, Fukutake S, et al. Focused Ultrasound Thalamotomy for Tremor-dominant Parkinson’s Disease: A Prospective 1-year Follow-up Study. Neurol Med Chir (Tokyo). 2021;61(7):414-421.  https://doi.org/10.2176/nmc.oa.2020-0370
  70. Galimova RM, Illarioshkin SN, Buzaev IV, et al. Therapy of movement disorders by MR-Guided Focused Ultrasound. Recommendations for neurologists on the selection of patients. Bjulleten’ Nacional’nogo obshhestva po izucheniju bolezni Parkinsona i rasstrojstv dvizhenij. 2020;1:9-15. (In Russ.). https://doi.org/10.24411/2226-079X-2020-12168

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.